Helixxa Certified to Provide NimbleGen Array Services in Brazil

MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen (SIX: RO),(SIXROG),(OTCQX: RHHBY) is pleased to announce that São Paulo-based genomic services provider Helixxa has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. Helixxa has been certified to process customer samples for NimbleGen Gene Expression arrays in their lab outside of São Paulo. Helixxa is the first and only genomics service provider in Latin America, as well the only provider in the region that offers multiple Roche Applied Science products including: 454 Genome Sequencer FLX, MagNA Pure, LightCycler®, and MagNA Lyser. Helixxa’s team of experts are experienced at performing high-quality services for many different customer segments, which include academic research, medical research, agri-business, and pharmaceutical and consumer goods industries.

“We are extremely grateful and excited for this partnership with Roche NimbleGen. Our commitment to excellence and the expertise of our team will provide the LATAM life science market with the genomic tools and knowledge to further research in this exciting, emerging market. We are extremely excited to offer the NimbleGen Gene Expression and CGH arrays to the Brazilian and Latin American market as we believe they provide the most comprehensive and robust solution for life sciences applications” said Mario Antonio de Oliveira Jr., CEO at Helixxa.

“Roche NimbleGen is extremely excited to welcome Helixxa as our first certified service provider in Latin America for gene expression and comparative genome hybridization applications. This partnership with Helixxa represents a significant step forward positioning Roche NimbleGen for aggressive expansion into the rapidly growing genomics market in Brazil and Latin America" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Helixxa
Helixxa is located in Campinas, within the state of São Paulo and is Brazil’s first genomic service provider. Throughout the world, genomics has been a priority with large government and multinational investments and has been showing great profitability in several countries. Helixxa is fundamental in these efforts, whereby they supply and partner for providing genomic service solutions with key industrial markets, academic research, and health proposals. Helixxa specializes in providing services (sequencing, SNPs and genotyping analysis, DNA and RNA analysis, complete genomes, etc.) for furthering our understanding of diseases and predispositions in humans, animals, plants and other living organisms. Helixxa provides large-scale and high throughput analysis, with complete and reliable information (bioinformatics inclusive), ensuring transparency and simplicity on the understanding of information. Visit www.helixxa.com for more information.

For life science research only. Not for use in diagnostic procedures.

LIGHTCYCLER, MAGNA LYSER, MAGNA PURE, and NIMBLEGEN are trademarks of Roche.
Other brands or product names are trademarks of their respective holders.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49-8856-604830
Email: [email protected]
or
Roche NimbleGen
Kary Staples
Phone: +1-608-218-7623
Email: [email protected]

KEYWORDS:   United States  Brazil  Europe  North America  South America  Switzerland  Wisconsin

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.